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Abstract 
Background: Management guidelines were established in order to improve disease outcomes of 
Clostridioides difficile infection (CDI); however, recent studies suggest inferiority of oral 
metronidazole in the treatment of CDI, which brought into question its usefulness even for a first, 
non-severe CDI. We aimed to explore adherence of the initial CDI therapy to the current ESCMID 
treatment guidelines and to compare treatment outcomes of the first non-severe CDI episode 
between oral metronidazole and vancomycin group. 
Methods: This retrospective observational study included in-patients of all ages with laboratory 
confirmed CDI, treated at the University Hospital for Infectious Diseases, Zagreb, Croatia, from 2013 
to 2017. Statistical analysis was performed. 
Results: Among 1073 hospitalizations due to CDI the mean age was 71.4±17.4 years and females 
predominated (58.2%). Adherence to the treatment guidelines was found in 655/1073 (61.0%) of 
patients, being lowest among fulminant CDIs (20.5%). Groups treated initially with oral 
metronidazole (N=282) and oral vancomycin (N=78) for the first, non-severe CDI episode were 
comparable by clinical and epidemiological features (p>0.05). However, the initial treatment with 
oral metronidazole had to be changed to another therapy in 64/282 (22.7%) patients, mostly (33/64) 
due to clinical inefficiency and in 22/64 due to side effects, in comparison to only 2/78 (2.6%) who 
switched therapy in the vancomycin group. 
Conclusions: The low adherence to the treatment guidelines warrants additional education of the 
clinicians. The high rate of clinical inefficiency and unwanted side effects of oral metronidazole 
therapy make its usefulness doubtful, even for a first, non-severe CDI. 
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Introduction 
 Clostridioides difficile has become one of the most important healthcare-associated 
pathogens in both Europe and United States. Appearance of hypervirulent strains (i.e. BI/NAP1/027) 
has led to increased incidence, morbidity, mortality and economical impact of the disease.  
Management guidelines [1,2] were established in order to reduce morbidity and mortality of C. 
difficile infection (CDI) and their non-observance has been associated with poorer clinical outcomes 
[3]. The reported overall adherences are low [3-6], often even under 50% of CDI cases, and factors 
influencing therapeutical decisions being discordant to the guidelines are insufficiently explored.  
Although most of the recent studies have shown inferiority of oral metronidazole in comparison to 
oral vancomycin in treatment of severe/fulminant cases [7,8], clinical validity of its use in the first, 
non-severe CDI seems to be still an open question.   
This study aimed to explore adherence of the administered initial CDI therapy to the current 
European Society of Clinical Microbiology and Infectious Diseases clinical practice guidelines 
(ESCMID-CPG) [1], and to compare treatment outcomes of the first, non-severe CDI episodes 
between oral metronidazole and vancomycin group.  
Materials and methods 
 This retrospective observational study included in-patients of all ages with laboratory 
confirmed CDI, treated at the University Hospital for Infectious Diseases, Zagreb, Croatia in the 
period from 2013 to 2017. During 2013, the diagnosis was confirmed by enzyme immunoassay test 
for detection of A/B toxins from stool samples, while in the period 2014 - 2017 the two-step test was 
used (screening GDH test confirmed with toxin A/B PCR). Severity of the illness was classified 
according to Infectious Diseases Society of America/ Society for Healthcare Epidemiology of America  
clinical practice guidelines (IDSA/SHEA-CPG) formulations; the patients having fever (>38.5 °C), white 
blood cell count >15x109/L, and creatinine ≥133 µmol/L [2] were considered to have severe CDI. The 
observed groups were compared by initial disease severity and comorbidities using ATLAS and 
McCabe score. Oral metronidazole (500 mg 4 times per day) and oral vancomycin (125 mg 4 times 
per day) group were compared by following outcome indicators: intensive care unit (ICU) treatment 
due to CDI (yes/no), all-cause in-hospital mortality rate (%) and need for a change of initial 
treatment. Symptom progression or stagnation after five days of initial treatment was considered as 
„clinical inefficiency“. Changing oral vancomycin to the combination of oral vancomycin + 
intravenous metronidazole was also considered as a „switched therapy“. 
Results were analyzed using the SAS (version 9.4, SAS Institute, Cary, North Carolina, USA). 
Frequencies and percentages, means and standard deviations were calculated. Student t-test, chi-
square test, and linear regression method were used. P-value of less than 0.05 was considered as 
statistically significant. 
Results 
 Overall, there were 1073 treatments due to CDI in an observed period. The mean age was 
71.4±17.4 years and majority (58.2%) were female. 23 (2.1%) of the patients were aged 0–17 years, 
222 (20.7%) 18–64, 447 (41.7%) 65–79, and 381 (35.5%) ≥80 years. Majority had healthcare-
associated CDI (76.9%), 15.7% had community-associated, and 7.4% had epidemiologically 
undetermined CDI. 
Stratification of the patients by a number of CDI episode, disease severity, and adherence of the 
intial therapy to the ESCMID-CPG is shown in Table 1.  
Adherence to the ESCMID-CPG was found in 655/1073 (61.0%) of patients, and adherence increased 
with CDI episode number (56.3%, 62.1%, and 85.6% respectively; p=0.214). Adherence to the 
ESCMID-CPG differed significantly (p<.001) within each number-of-episode group according to the 
disease severity. Adherence to the guidelines was lowest in the fulminant CDI group (20.5%) whereby 
it was 21.6% for the first, 15.4% for the second and 25.0% for the ≥ third episode.  The overall initial 
undertreatment was observed in 320/1073 (29.8%) patients; in 9.6% of non-severe, 44.1% of severe 
and 79.5% of fulminant CDIs.  
In-hospital mortality rate decreased with the increase of the disease episode number and it was 
11.8%, 8.7% and 5.6% for the first, second and ≥third CDI episode, respectively (p<.001). The need 
for the ICU admission due to CDI also decreased with the number of the disease episode and it was 
2.7%, 0.8% and 0.8% for the first, second and ≥third CDI episode, respectively (p=0.105).  
Oral metronidazole and vancomycin groups of patients with first, non-severe CDI episode didnʹt 
differ signifficantly regarding mean age, McCabe score, ATLAS score, proportion of healthcare-
associated CDIs, need for ICU tretment due to CDI and in-hospital mortality rates (all p>0.05), but the 
initial treatment with metronidazole had to be changed significantly more often, as it is shown in 
Table 2.  
In patients with first, non-severe CDI initial oral metronidazole treatment was switched to another 
therapy in 64/282 (22.7%) of patients: in 33/282 (11.7%) due to clinical inefficiency, in 18/282 (6.4%) 
due to gastrointestinal side effects, in 4/282 (1.4%) due to allergic reaction and in 9/282 (3.2%) due 
to other/unrecorded reasons. In patients with first, non-severe CDI initial oral vacomycin treatment 
was switched to another therapy in 2/78 (2.6%) of patients: in one patient due to clinical inefficiency 
(1.3%) and in other due to gastrointestinal side effects (1.3%). In the group od patients with first, 
non-severe CDI oral metronidazole treatment was significantly more often clinically inefficient in 
comparison to oral vancomycin (p=0.005). 
Discussion 
 In comparison to the previous studies, in which adherence of the initial CDI treatment to the 
treatment guidelines ranged from 40.2 – 54.0% [3-6], in our tertiary care center specialized in 
infectious diseases the higher, but stil unsatisfactory adherence of 61% has been recorded.   
Studies analysing the gudelines adherence reported mostly its decrease with increase of disease 
severity [4,6], and the adherence as low as 8.5% in a group of severe CDI [4], along with adherence of 
16.6% in a group of fulminant CDI has been reported [5]. In a study from USA that analyzed patient 
factors which indicate provider's nonadherence to an institutional CDI treatment guidelines, bivariate 
analyses associated 5 factors with nonadherence: older age, ICU admission, duration of antibiotics 
and mild/moderate and severe infection (all p<.05), and in the logistic regression model, severe 
infection (p<.001) was independently associated with guideline nonadherence [6], which suggests 
disregarding of disease-severity criteria while choosing initial CDI therapy.   
Our results also indicate outweight of a number-of-disease-episode criteria above disease-severity 
criteria in decision making process, which has resulted in a high rate of undertreatment, especially in 
severe (44.1%) and fulminant (79.5%) CDI cases.  
The impaired clinical outcomes due to disregard of CDI treatment guidelines, especially among more 
severe ill patients, have been observed by numerous studies [3,5]. The disease outcomes can be 
influenced by many predisponing factors existing in a patient, and by clinical burden of the disease 
per se, but the negative clinical impact of the initial undertreatment of CDI infection should also be 
taken into the consideration. It seems that the rate of unfavorable outcomes could be reduced by 
familiarization of the attending physicians with the treatment guidelines, and by increased use of CDI 
severity criteria while making therapeutic decissions. 
Recently, a randomized, placebo-controlled trial has shown that oral vancomycin (259 patients) was 
superior to metronidazole (278 patients); overall clinical success was 81.1 vs. 72.7% (p=.02), 
respectively; however, the significant difference was not confirmed in a subgroup of severe CDIs [9]. 
Superiority of oral vancomycin vs. metronidazole only in a subgroup of severe CDIs has been 
reported recently in a large meta-analysis which included five randomized controlled trials (risk ratio: 
1.19, 95% CI: 1.02-1.39, p=0.03), and in a retrospective, propensity-matched cohort study evaluating 
2068 patients treated due to first CDI episode with oral vancomycin matched to 8069 patients in the 
metronidazole group (adjusted relative risk for all-cause 30-day mortality, 0.79; 95% CI, 0.65 to 0.97; 
adjusted risk difference, -0.04; 95% CI, -0.07 to -0.01) [7,8]. On the contrary, one retrospective study 
analysing 168 patients with mild/moderate CDI (NAP1 n = 85, non-NAP1 n = 83) showed higher rate 
of treatment response in oral vancomycin vs. oral metronidazole group (97% vs. 82%, p=0.002) [10], 
as our study did.    
The latest (2017) update of IDSA/SHEA-CPG recommend oral vancomycin as a first choice treatment 
in a first, non-severe CDI episode, while current European ESCMID-CPG (2013) for the same 
indication recommend metronidazole [1,2]. However, there is an additional recommendation in 
ESCMID-CPG to prefer the use of oral vancomycin in a tretment of non-severe CDI in a patients with 
increased risk for recurrent disease (age >65 years, continued use of non-CDI antibiotics after 
diagnosis of CDI, and/or after CDI treatment, severe underlying disease and/or renal failure, a history 
of previous CDI, concomitant use of antacid medications) [1], which hugely reduces 
recommendations for metronidazole use, complicating simultaneously the decision making process 
and likely decreasing the guidelines adherence.  Besides rising resistance of C. difficile, common 
gastrointestinal side-effects, concommitant restriction of alchocol use and, due to its bountifull 
apsorption in the gut, its increased potential for systemic allergic reactions and rare, but serious, 
neurotoxicity, in addition to suggested decreased clinical efficacy in a treatment of non-severe CDIs, 
the place of metronidazole in ESCMID-CPG seems to be questionable. As the strongest argument for 
metronidazole use in this indication remains its much lower cost in comparison to vancomycin 
capsules, which can be overbridged by the oral use of much cheaper liquid intravenous vancomycin 
compositions.  
Conclusions 
 The additional effort should be putted to increase the adherence to the CDI treatment 
guidelines (i.e. increase of the guidelines practicality, education of the attending clinicians - especially 
to obey the disease-severity criteria, etc.) which could improve clinical outcomes. The notable rate of 
clinical inefficiency and unwanted side effects of oral metronidazole therapy observed in our study 
confirmes doubtfulness of its use, even for a treatment of first, non-severe CDI. 
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Table 1. Initial therapy for Clostridioides difficile infection according to the number of episode, 
severity of illness and adherence to the ESCMID clinical practice guidelines 
 
Number of 
CDI† episode 
 
Oral 
metronidazole 
(N=549) 
Oral 
vancomycin 
(N=479) 
Metronidazole iv.§ 
+ oral vancomycin 
(N=45) 
Total 
(N=1073) 
First (N=695)  
Non-severe N (%) 282 (77.7)* 78 (21.5) 3 (0.8) 363 (100) 
Severe N (%)  147 (60.2) 90 (36.9)* 7 (2.9) 244 (100) 
Fulminant N (%)  37 (42.0) 32 (36.4) 19 (21.6)* 88 (100) 
Second (N=253)  
Non-severe N(%) 50 (35.7) 86 (61.4)* 4 (2.9) 140 (100) 
Severe N (%)  17 (19.5) 67 (77.0)* 3 (3.4) 87 (100) 
Fulminant N (%)  6 (23.1) 16 (61.5) 4 (15.4)* 26 (100) 
≥ Third (N=125)  
Non-severe N (%) 5 (7.5) 61 (91.0)* 1 (1.5) 67 (100) 
Severe N (%)  4 (8.0) 44 (88.0)* 2 (4.0) 50 (100) 
Fulminant N (%)  1 (12.5) 5 (62.5) 2 (25.0)* 8 (100) 
Total N (%)  549 (51.2) 479 (44,6) 45 (4,2) 1073 (100) 
*initial treatment accordant to the ESCMID guidelines; †Clostridioides difficile infection; §intravenous 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Comparison of the epidemiological, clinical and outcome parameters among patients with 
the first non-severe episode of the Clostridioides difficile infection treated with oral metronidazole 
and oral vancomycin 
Variables Oral metronidazole  
(N=282) 
Oral vancomycin  
 (N=78) 
P value 
 mean±SD* mean±SD  
McCabe score 1.3±0.7 1.3±0.6 1.000 
ATLAS score 4.1±1.9 4.5±1.9 0.102 
Age (years) 66.8±20.9 66.7±20.4 0.970 
 N (%) N (%)  
Healthcare-associated CDI 184 (65.2) 59 (75.6) 0.083 
ICU treatment due to CDI 1 (0.4) 0 0.577 
In-hospital mortality rate 6 (2.1) 1 (1.3) 0.649 
Change of initial treatment (yes) 64 (22.7) 2 (2.6) <.001 
*standard deviation 
 
 
 
 
 
 
 
